The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -62,845 | - |
| Depreciation | 555 | 1,247 |
| Noncash operating lease expense | 973 | 2,030 |
| Stock-based compensation | 6,625 | 13,825 |
| Accretion on marketable securities | -560 | -1,360 |
| Net loss | - | -78,729 |
| Other, net | 1 | 57 |
| Prepaid expenses and other current assets | 1,652 | 461 |
| Other long-term assets | -20 | 306 |
| Accounts payable | -344 | 750 |
| Accrued expenses and other liabilities | 1,604 | -4,988 |
| Operating lease liabilities | -245 | -1,594 |
| Deferred revenue | -53,811 | -8,573 |
| Net cash used in operating activities | -30,952 | -78,216 |
| Purchase of property and equipment | 151 | 675 |
| Sales and maturities of marketable securities | 65,965 | 119,150 |
| Purchases of marketable securities | 18,337 | 71,100 |
| Net cash provided by investing activities | 47,477 | 47,375 |
| Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under espp | 2,541 | 583 |
| Net cash provided by financing activities | 2,541 | 583 |
| Net change in cash, cash equivalents and restricted cash | 19,066 | -30,258 |
| Cash and cash equivalents at beginning of period | 72,097 | - |
| Cash and cash equivalents at end of period | 60,905 | - |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)